CDKN2A antibody from Promab.
Know who made it. See the evidence. Buy through one marketplace.
Capable of inducing cell cycle arrest in G1 and G2 phases. CDKN2A acts as a tumour suppressor. CDKN2A binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus.
For research use only.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC | IHC-P | IHC-F | IF/ICC | Flow Cytometry | ELISA | IP | ChIP |
|---|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by Promab and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
CDKN2A identifies cyclin dependent kinase inhibitor 2A in Homo sapiens (Human). This target record connects NCBI Gene 1029, UniProtKB P42771 and related ABMIUM catalogue products.
